Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat
https://www.zacks.com/stock/news/2268089/puma-biotechnology-s-pbyi-q1-earnings-and-revenues-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2268089
May 03, 2024 - Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.
0
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
https://www.zacks.com/stock/news/2267253/alkermes-alks-q1-earnings-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2267253
May 02, 2024 - Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
0
Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates
https://www.zacks.com/stock/news/2267317/jazz-jazz-q1-earnings-sales-fall-short-of-estimates?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2267317
May 02, 2024 - Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.
0
Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates
https://www.zacks.com/stock/news/2267231/repligen-rgen-q1-earnings-miss-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2267231
May 02, 2024 - Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.
0
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
https://www.zacks.com/stock/news/2267310/moderna-mrna-q1-earnings-beat-estimates-revenues-down-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2267310
May 02, 2024 - Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
0
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
https://www.zacks.com/stock/news/2267221/sarepta-srpt-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2267221
May 02, 2024 - Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
0
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
https://www.zacks.com/stock/news/2263560/sage-therapeutics-sage-q1-earnings-miss-sales-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2263560
Apr 26, 2024 - Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
0
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
https://www.zacks.com/stock/news/2260461/corcept-cort-posts-positive-data-from-cushing-s-syndrome-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260461
Apr 23, 2024 - Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
0
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
https://www.zacks.com/stock/news/2260438/sanofi-sny-rilzabrutinib-shows-benefit-in-blood-disorder-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260438
Apr 23, 2024 - Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
0
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
https://www.zacks.com/stock/news/2259547/will-alkermes-alks-proprietary-drugs-aid-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-2259547
Apr 22, 2024 - Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
0
Page 1>